Skip to content
Noro-Moseley Partners logo
Private EquityExempt Reporting Adviser · CRD 162877Private Fund Adviser

Updated:

Noro-Moseley Partners

Noro-Moseley Partners provides early growth equity for rapidly-scaling B2B technology and healthcare companies. The firm has been partnering with exceptional...

Overview

Noro-Moseley Partners provides early growth equity for rapidly-scaling B2B technology and healthcare companies. The firm has been partnering with exceptional teams since 1983 and works with strong CEOs of high-growth businesses to scale. It actively invests in businesses with 50%+ year-over-year growth, compelling unit economics, target revenue run rates of $2M–20M, and target investments of $5–20M.

General information

Firm type

Private Equity

Year founded

1983

Location

Region

North America

Country

United States

City

Atlanta

Corporate office

Atlanta, GA, United States

Sector focus

Enterprise SoftwareHealthcare ServicesAI/MLDigital Health

Frequently asked questions

How does Noro-Moseley Partners source its healthcare deals?

NMP cultivates distribution relationships with a curated group of health-plan and health-system investors that collectively cover 45 million lives, giving portfolio companies direct access to enterprise healthcare purchasers. The firm also draws on its 40-year network and the domain expertise of its operating advisor group to identify businesses with proven unit economics before they pursue institutional capital.

How involved does Noro-Moseley get with portfolio company operations?

NMP takes an active board role focused on CEO support, executive team recruitment, sales and marketing instrumentation, and exit-process management. The firm provides operating advisors who are former entrepreneurs and executives, and it has guided multiple companies through transitions from services to SaaS models before exit.

Does Noro-Moseley Partners invest outside the United States?

NMP invests exclusively in US-headquartered companies, with active portfolio operations in Texas, New York, Ohio, Michigan, Minnesota, Florida, Georgia, Idaho, and North Carolina. The firm describes its geographic focus as emerging technology and healthcare hubs across the United States.

What is the firm's realized exit track record?

The current NMP team has generated exits representing over $5 billion in aggregate enterprise value since 2015 (per firm website). Notable realized exits include Red Canary (acquired by Zscaler), Contessa (acquired by Amedisys), SupplyPike (acquired by SPS Commerce), Clearleap (acquired by IBM), and Trendkite (acquired by Cision).

Who leads investment decisions at Noro-Moseley Partners?

NMP's public team page describes the group as having over 70 years of collective investment experience, but the firm does not name individual managing partners, general partners, or an investment committee on its website. Investment decisions appear to be made collaboratively by the core investment team based in Atlanta.

What sectors does Noro-Moseley explicitly avoid?

NMP restricts its mandate to B2B technology and healthcare companies, including enterprise software, AI-enabled platforms, healthcare IT, and tech-enabled services. The firm has no disclosed interest in consumer-facing businesses, hardware, deep tech outside of AI/ML, or capital-intensive sectors like manufacturing.

Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.

Need institutional-grade insight on private equity firms?

Altss delivers:

Principals with verified direct contactsAllocation history by asset classOSINT-derived deal signals
Book a demo

Prefer a guided tour?

We’ll walk you through:

Interactive funding timelinesCustom mandate & allocation filters
Book a demo

Browse by category

More Private Equity profiles